Multi‐Cellular Human Liver Organoids for Modeling Metabolic Dysfunction–Associated Steatotic Liver Disease and Drug‐Induced Liver Injury
Current Protocols · 2026-01 · 6 (1)
DOI: 10.1002/cpz1.70294 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Protocols, online erschienen am 19.01.2026. Verfasst von Maela Duclos und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institut NuMeCan (Nutrition, Metabolisms and Cancer), INSERM 1317, UMR INRAE 1341, Université de Rennes, Rennes, France. Hauptthemen laut MEDLINE: Organoids, Fatty Liver, Chemical and Drug Induced Liver Injury, Liver. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
In vitro modeling of human liver function is essential for assessing drug‐induced toxicity, particularly in the context of metabolic dysfunction–associated steatotic liver disease (MASLD). However, standard liver organoid systems often lack xenobiotic‐metabolizing enzyme activity and fail to replicate the pathological features of MASLD. Here, we present a method for generating functional, multi cell–type human liver organoids (HML) organoids from HepaRG cells, primary human macrophages, and LX‐2 hepatic stellate cells. These three‐dimensional (3D) organoids are cultured under defined conditions that support key hepatic functions. To mimic MASLD, we expose HML organoids to a mixture of stearic and oleic acids for 9 days, inducing steatosis and fibrogenic responses characteristic of the disease. These MASLD‐HML organoids retain liver‐specific functions and express key fibrosis markers. We further demonstrate the usefulness of this method to produce standardized organoids useful for the evaluation of drug‐induced liver injury (DILI) through IC50 and benchmark dose calculations, particularly in the context of MASLD. Together, HML and MASLD‐HML organoids provide a robust model for studying drug metabolism, toxicity, and adverse drug reactions in healthy and diseased liver states. © 2026 Wiley Periodicals LLC. Basic Protocol 1 : Culture of HepaRG cells Basic Protocol 2 : Culture of LX‐2 cells Basic Protocol 3 : Culture of primary human unstimulated M1 macrophages Basic Protocol 4 : Organoid seeding procedure 1 in agarose molds Basic Protocol 5 : Organoid seeding procedure 2 in ultra‐low attachment 96‐well plate Alternate Protocol : Organoid seeding procedure from cryopreserved cells Basic Protocol 6 : Preparation of the fatty acid mixture Basic Protocol 7 : MASLD induction
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institut NuMeCan (Nutrition, Metabolisms and Cancer), INSERM 1317, UMR INRAE 1341, Université de Rennes, Rennes, France.
- Toxicology of Contaminants Unit, Fougères Laboratory, French Agency for Food, Environmental and Occupational Health & Safety (ANSES), Fougères, France.
ORCID-Profile: Zeineb Marzougui, Pierre-Jean Ferron
Zitieren
APA
Duclos, M., Marzougui, Z., Saleh, M., Corlu, A., Massart, J., & Ferron, P. J. (2026). Multi‐Cellular Human Liver Organoids for Modeling Metabolic Dysfunction–Associated Steatotic Liver Disease and Drug‐Induced Liver Injury. Current Protocols, 6(1). https://doi.org/10.1002/cpz1.70294
Vancouver
Duclos M, Marzougui Z, Saleh M, Corlu A, Massart J, Ferron PJ. Multi‐Cellular Human Liver Organoids for Modeling Metabolic Dysfunction–Associated Steatotic Liver Disease and Drug‐Induced Liver Injury. Current Protocols. 2026;6(1). doi:10.1002/cpz1.70294
BibTeX
@article{Duclos2026,
author = {Duclos, Maela and Marzougui, Zeineb and Saleh, Mariam and Corlu, Anne and Massart, Julie and Ferron, Pierre-Jean},
title = {Multi‐Cellular Human Liver Organoids for Modeling Metabolic Dysfunction–Associated Steatotic Liver Disease and Drug‐Induced Liver Injury},
journal = {Current Protocols},
year = {2026},
volume = {6},
number = {1},
doi = {10.1002/cpz1.70294}
}
EUVIMED